Drawing for ONE PARTNER

USPTO serial 78346065

ONE PARTNER

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
FINK, GINA M
Law office
TMEG LAW OFFICE 103 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ONE PARTNER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Arlene D. Hanks

Goods and services

ClassDescriptionStatusFirst use
035business services in the pharmaceutical, biotechnology and life sciences fields, namely, advising and assisting clients in the development and commercialization of products and management of product portfoliosACTIVE—
036providing financial services in the pharmaceutical, biotechnology and life sciences fields; namely, providing financing to pharmaceutical, biotechnology and life sciences companies for product development and commercialization, making acquisitions of products and product rights of and investments in pharmaceutical, biotechnology and life sciences companies and indirect investments in life science venture funds to aid pharmaceutical, biotechnology and life sciences companies in the development and commercialization of new products, management of product portfolios, prioritization of financial resources and achievement of financial objectives and providing financial consultation in connection therewithACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Mar 2, 2005MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 2, 2005ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 29, 2004GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 26, 2004DOCKASSIGNED TO EXAMINER—
Jun 15, 2004MAILPAPER RECEIVED—
Jan 8, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance